Two drugs used to treat high blood pressure and depression are to be withdrawn from the Taiwanese market from late this year to early next year, but locally produced generics would fill the gap, the Food and Drug Administration (FDA) said on Monday.
The manufacturers notified the agency that they would stop providing Aprovel 150mg film-coated tablets, an antihypertensive, and Prozac Dispersible 20mg tablets, an antidepressant, after December and November respectively, FDA Deputy Director-General Wang Te-yuan (王德原) said.
The two companies informed the FDA on July 31 and June 24 respectively, he added.
Photo: Chiu Chih-jou, Taipei Times
However, the supply of the two drugs would not be affected, because they would be replaced by generic alternatives produced by local pharmaceutical companies, Wang said.
Generics have the same effects as brand-name drugs and are produced by other qualified pharmaceutical manufacturers using the same ingredients and procedures after the original patents expire, the Taiwan Generic Pharmaceutical Association said.
Aprovel 150mg film-coated tablets last year had a 67 percent share of the Taiwanese market, with 1.24 million tablets covered by National Health Insurance, said Tai Hsueh-yung (戴雪詠), an official from the National Health Insurance Administration’s (NHIA) Medical Review and Pharmaceutical Benefits Division.
The manufacturer of Aprovel 150mg tablets on April 1 proposed that the National Health Insurance Administration remove the drug from NHI coverage, and replace it with drugs that contain the same ingredients, Tai said.
Clinicians in Taiwan have supported that advice, saying that there are several generic drugs available, while the Pharmaceutical Benefit and Reimbursement Scheme Joint Committee approved the proposal during in June. The drug is to be removed from NHI coverage in January next year.
There are nine drugs covered by the NHI that contain the same active ingredients as Aprovel, Tai said.
Meanwhile, the NHI covers 11 alternatives to Prozac, which last year had a 15.3 percent market share with 2.92 million tablets covered by the NHI, Tai said.
Nearly 40 years have passed since Prozac first entered the market, and the market share of generic versions in Taiwan has reached 85 percent, Tai said.
In other news, the NHIA said that it would evaluate whether to include a one-time gene therapy to treat people with hemophilia B in the NHI drug reimbursement scheme, after it is approved in Taiwan.
The US Food and Drug Administration has approved the gene therapy fidanacogene elaparvovec (Beqvez), which has a hefty US$3.5 million price tag, for adults with hemophilia B, a rare bleeding disorder.
The therapy has only received conditional marketing authorization from the European Commission under the name Durveqtix because it was tested on a small number of people, Tai said.
The manufacturer of Beqvez is required to continue providing data on the treatment’s long-term efficacy, she said.
Applications for importing the one-time hemophilia B gene therapy product have been submitted to Taiwan’s Food and Drug Administration, Tai said.
If the suppliers submit reimbursement applications to the NHIA after an import permit is granted, the agency would begin evaluating the efficacy of the treatment, its cost-effectiveness and the extent to which it enhances a patient’s quality of life, Tai said.
Hemophilia B is a rare inherited disease caused by a deficiency or defect in blood clotting factor IX, meaning the blood cannot clot properly to control bleeding.
People with severe hemophilia B often receive regular infusions to prevent bleeding episodes. The disease affects 196 people in Taiwan, and the average annual cost of their treatments is about NT$5 million to NT$7 million (US$156,284 to US$218,798).
Although Beqvex costs about NT$100 million, the one-time gene therapy is intended to help people produce factor IX, rather than needing infusions multiple times a week.
GREAT POWER COMPETITION: Beijing views its military cooperation with Russia as a means to push back against the joint power of the US and its allies, an expert said A recent Sino-Russian joint air patrol conducted over the waters off Alaska was designed to counter the US military in the Pacific and demonstrated improved interoperability between Beijing’s and Moscow’s forces, a national security expert said. National Defense University associate professor Chen Yu-chen (陳育正) made the comment in an article published on Wednesday on the Web site of the Journal of the Chinese Communist Studies Institute. China and Russia sent four strategic bombers to patrol the waters of the northern Pacific and Bering Strait near Alaska in late June, one month after the two nations sent a combined flotilla of four warships
THE TOUR: Pope Francis has gone on a 12-day visit to Indonesia, Papua New Guinea, East Timor and Singapore. He was also invited to Taiwan The government yesterday welcomed Pope Francis to the Asia-Pacific region and said it would continue extending an invitation for him to visit Taiwan. The Ministry of Foreign Affairs made the remarks as Pope Francis began a 12-day tour of the Asia-Pacific on Monday. He is to travel about 33,000km by air to visit Indonesia, Papua New Guinea, East Timor and Singapore, and would arrive back in Rome on Friday next week. It would be the longest and most challenging trip of Francis’ 11-year papacy. The 87-year-old has had health issues over the past few years and now uses a wheelchair. The ministry said
TAIWANESE INNOVATION: The ‘Seawool’ fabric generates about NT$200m a year, with the bulk of it sourced by clothing brands operating in Europe and the US Growing up on Taiwan’s west coast where mollusk farming is popular, Eddie Wang saw discarded oyster shells transformed from waste to function — a memory that inspired him to create a unique and environmentally friendly fabric called “Seawool.” Wang remembered that residents of his seaside hometown of Yunlin County used discarded oyster shells that littered the streets during the harvest as insulation for their homes. “They burned the shells and painted the residue on the walls. The houses then became warm in the winter and cool in the summer,” the 42-year-old said at his factory in Tainan. “So I was
‘LEADERS’: The report highlighted C.C. Wei’s management at TSMC, Lisa Su’s decisionmaking at AMD and the ‘rock star’ status of Nvidia’s Huang Time magazine on Thursday announced its list of the 100 most influential people in artificial intelligence (AI), which included Taiwan Semiconductor Manufacturing Co (TSMC) chairman and chief executive officer C.C. Wei (魏哲家), Nvidia CEO Jensen Huang (黃仁勳) and AMD chair and CEO Lisa Su (蘇姿丰). The list is divided into four categories: Leaders, Innovators, Shapers and Thinkers. Wei and Huang were named in the Leaders category. Other notable figures in the Leaders category included Google CEO Sundar Pichai, Microsoft CEO Satya Nadella, OpenAI CEO Sam Altman and Meta CEO and Facebook founder Mark Zuckerberg. Su was listed in the Innovators category. Time highlighted Wei’s
RSS